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Abstract 
Obstructive sleep apnea (OSA) as a worldwide prevalent condition carries risk for 
cardiovascular and metabolic diseases, ultimately increasing overall mortality rates. Non-
alcoholic fatty liver disease (NAFLD) can be considered as the primary metabolic disease, but 
also as a coexisting OSA comorbidity. Although prevalence of NAFLD covers quarter of world 
population, it increases with OSA presence. It can be speculated that chronic intermittent hypoxia 
(CIH) and sympathetic nervous system overactivity are involved in NAFLD pathogenesis and 
progression from simple steatosis through steatohepatitis to fibrosis. CIH provides the 
environment for liver oxidative stress, inflammation and increases the expression of genes 
involved in cholesterol and fatty acids synthesis. Catecholamines increase β-oxidation in liver and 
release free fatty acids from adipose tissue in plasma which inhibit insulin effects. Obesity and 
insulin resistance as key players in NAFLD development and advancement, deepen vicious circle 
of oxidative stress, inflammation and dyslipidemia. If not treated, OSA in NAFLD patients has 
been associated with inflammation, hepatocytes’ necrosis, and fibrosis. Continuous positive 
airway pressure (CPAP) represents gold standard for OSA therapy, allowing the unimpeded air 
passage through upper parts of respiratory system. However, it has been demonstrated that CPAP 
therapy have beneficial effects on cardiometabolic outcomes and slow liver degeneration. 
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Obstructive sleep apnea (OSA) 
Obstructive sleep apnea (OSA) is characterized by the partial (hypopnea) or 
complete (apnea) cessation of the air passage through the upper parts of the respiratory 
system, which occurs due to the collapse of the pharynx during sleep (1). Anatomic 
(enlarged tonsils, tongue volume, pharynx lateral walls, and maxilla abnormal 
positioning) and neuromuscular factors (reduced pharynx neuromuscular activity and 
pharyngeal dilator muscle hypotonia) mainly participate in the collapse of the pharyngeal 
soft structures. Due to the reduced respiratory muscle tone, there is also a reduced 
ventilation volume during sleep. Low respiratory volume and minute ventilation cause a 
decrease in the partial pressure of oxygen in the blood (hypoxemia), and an increase in 
the partial pressure of carbon dioxide in the blood (hypercapnia) (1). The other 
consequences of this condition are variations in intrathoracic pressure, chronic 
intermittent hypoxia (CIH), sleep fragmentation, and chronic daytime sleepiness. 
However, the prevalence of OSA worldwide increases with obesity (2). This condition is 
a risk factor for endothelial dysfunction, atherosclerosis, and cardiovascular diseases 
(hypertension, arrhythmia, stroke, coronary heart disease) (3). Also, it is in tight linkage 
with insulin resistance and type 2 diabetes mellitus (4), non-alcoholic fatty liver disease 
(NAFLD) (5), and dyslipidemia (6). OSA is more frequent in males, older age, individuals 
with larger neck circumference, and in cigarettes, and alcohol consumers (7-9).  
Several recent studies have indicated that the prevalence of the disease is between 
4-24% for men and 2-9% for women (10). Approximately 1 in 5 adults has a mild form 
of OSA, and 1 in 15 has a moderate or severe form (10) when the severity of OSA is 
assessed by the apnea-hypopnea index (AHI) which is defined by the number of 
objectively registered apnea or hypopnea interruptions of breathing per hour during sleep 
(1). Close to 70% of OSA patients are obese (11). 
Non-alcoholic fatty liver disease (NAFLD) 
NAFLD is one of the most common liver diseases comprises of a wide range of 
histopathological changes in the liver (12). The disease progresses during a longer period 
from simple steatosis (the triglycerides accumulation in lipid droplets within hepatocytes) 
through hepatocellular injury and lobular inflammation (non-alcoholic steatohepatitis or 
NASH), fibrosis, and ultimately to liver cirrhosis which could potentially lead to 
hepatocellular carcinoma (HCC) (13). NAFLD is a complex and multifactorial disease. 
Different suggestions had been proposed, but the widely accepted hypothesis for NAFLD 
development was the “two hits hypothesis”. The “first hit” occurs due to the presence of 
obesity and insulin resistance leading to an accumulation of triglycerides and the 
appearance of steatosis. This potentiates further insults of the liver by the “second hit” 
which comprises activated pro-inflammatory pathways, mitochondrial dysfunction, and 




fibrogenesis (13). This seemed quite a simple scenario for such a complex disease. 
Recently, the “two hits hypothesis” was replaced by the “multiple hits hypothesis” 
suggesting that many factors acting solely and in a synergistic manner with each other by 
different cellular signalling pathways predispose NAFLD development and progression 
from steatosis to fibrosis (14).  
Although insulin resistance is a key player in NAFLD development many other 
factors could initiate and potentiate its development and progression such as obesity, diet, 
gut microbiota, genetic and epigenetic factors as well as OSA (13,14). NAFLD is also 
closely related to type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases, 
and chronic kidney disease (15). The most studied NAFLD risk factors are displayed in 
Figure 1. In many individual cases, NAFLD could progress to chronic liver disease. 
 
 
Figure 1.  Risk factors associated with non-alcoholic fatty liver disease 
 






Therefore, NAFLD represents a global burden to public health in developed and 
developing countries (12). NAFLD prevalence of 25% has been documented in the 
European population. 60% to 75% of NAFLD patients are obese. Alarming data 
published in a recent meta-analysis indicated an increase in NAFLD prevalence in 
children and adolescents. NAFLD had 7.6% of children in the general population with an 
increased rate of up to 34.2% in obese. Close to 10% of patients with simple steatosis 
progress to the more severe form, NASH, and 20 % of them to HCC. Patients with 
NAFLD have no or nonspecific symptoms (12). Biochemistry testing of the liver’s 
enzyme profile, especially when aminotransferase activities are elevated could be the 
indication for liver ultrasound examination for detection of possible steatosis (13,14). 
However, neither ultrasound nor high aminotransferase activities could differentiate 
simple steatosis from NASH and even those with advanced fibrosis. Alanine 
aminotransferase (ALT) is usually elevated in progression from steatosis to 
steatohepatitis, but normal ALT activities do not exclude either steatosis or NASH. When 
steatosis and NASH are present, the aspartate aminotransferase (AST)/ALT ratio is 
typically less than 1 (16). The fibrosis staging without biopsy could be performed using 
fibrosis 4 (FIB-4) index (17) (calculation includes age, ALT, AST, and platelet count) 
and BARD score (calculation includes body mass index, diabetes, AST, and ALT) (18). 
AST-to-platelet ratio can be applied for predicting fibrosis and cirrhosis (19). The gold 
standard diagnostic method for NAFLD is a liver biopsy. Although it is the most reliable 
method when performed by an experienced doctor, it has significant shortcomings such 
as invasiveness, bleeding, pain, infection and in a small percentage even lethal outcome. 
Therefore, various scoring systems for diagnosis and prognosis of NAFLD are 
increasingly used to replace liver biopsy (20). 
Chronic intermittent hypoxia – central event of cardiometabolic 
 disturbances in OSA 
Definite mechanisms by which OSA leads to cardiometabolic disturbances are not 
completely elucidated. The main role could be probably assigned to CIH  linking OSA to 
the development and advancement of dyslipidemia, inflammation, and oxidative stress 
(21). 
Prolonged intermittent hypoxia, which can be measured as reduced peripheral 
oxyhemoglobin saturation, induces recurrent hypoxic and reoxidation states in blood and 
tissues. Such repetitive cycles cause the development of oxidative stress, which further 
interfere with organs and cell functions and metabolism. Oxidative stress is worsened by 
an increased sympathetic activation induced by negative intrathoracic pressure and 
recurrent awakenings during sleeping. Oxidative stress causes lipid peroxidation, protein, 
and deoxyribonucleic acid damage leading to cell apoptosis and necrosis. Furthermore, 




of pro-inflammatory adipocytokines, adhesion molecules, and procoagulants (22,23). An 
inflammatory response occurs due to the activation of the transcription factor nuclear 
factor (NF)-kB, which stimulates pro-inflammatory genes expression such as interleukin 
(IL)-1, IL-6, IL-8, tumour necrosis factor-α (TNF-α), resistin, etc. from circulating 
monocytes (23) and macrophages (including Kupffer cells). Indeed, not only Kupffer 
cells but also hepatocytes in acute liver injury synthesize IL-6 to establish normal hepatic 
function and to induce production of acute-phase proteins (24). However, in the chronic 
course of OSA, IL-6 in an autocrine and paracrine manner maintains inflammation (25). 
C reactive protein (CRP) which is a significant serum marker of inflammation, together 
with IL-6 reflect the degree of the inflammatory response (25,26). 
CIH via oxygen responsive hypoxia-inducible factor 1 (HIF-1) induces expression 
of key transcriptional factors and enzymes involved in lipid metabolism such as sterol 
regulatory element-binding protein 1 (SREBP-1), stearoyl-coenzyme A desaturase 1 
(SCD-1), and fatty acid synthase (27). SREBP1 transcription factor increases the 
synthesis of triglycerides, phospholipids, and fatty acids. SCD-1 converts saturated to 
monounsaturated fatty acids which, when increased, lead to a higher synthesis of 
cholesterol esters and triglycerides. Increased numbers of very-low-density lipoprotein 
(VLDL) particles persist in the circulation. Due to the inhibition of lipoprotein lipase by 
CIH, the clearance of chylomicrons and VLDL particles is decreased and their levels in 
circulation rise. Oxidative stress present in OSA leads to oxidative modification of 
lipoproteins making them more resistant to clearance from the bloodstream and more 
proatherogenic (28). Activated sympathetic nervous system via catecholamines increases 
lipolysis by activating hormone-sensitive lipase in adipose tissue and the efflux of free 
fatty acids in the circulation. Excess amounts of free fatty acids metabolites (acyl- 
coenzyme A and diacylglycerol) in the liver and skeletal muscles inhibit the effects of 
insulin on glucose uptake and on glycogen synthesis (29). Even more, they express a 
harmful influence on the pancreas to release an insufficient quantity of insulin to 
counteract hyperglycemia (15,29). This scenario includes both, peripheral and hepatic 
insulin resistance. 
Physiopathology link between OSA and NAFLD  
The liver has a double blood supply, by hepatic artery and portal vein. Hepatocytes 
close to the portal triad receive blood rich in oxygen and are involved in oxidative 
metabolism, bile, and glucose syntheses (30). Hepatocytes close to the central vein have 
poor oxygen supply, mediate glucose uptake and glycogen synthesis. This makes the liver 
sensitive not only to hypoxemia present in OSA but to oscillations in oxygen supply, 
especially its periportal zones (30,31).  
Many studies were conducted to establish potential associations between elevated 




affected only by a severe form of OSA, but not by mild and moderate. AST, however, 
showed no association with OSA status (32). Norman and colleagues demonstrated that 
lower oxygen saturation levels (below 90%), but not AHI, were independently related to 
higher AST and ALT levels (33). In the other study, only AHI greater than 50 was a 
stronger predictor for elevated liver enzymes than body mass index (34). The rise of 
hepatocytes cytosolic enzymes in plasma (ALT and AST), could signify plasma 
membrane damage, the release of enzymes in blood, and consequently cell apoptosis 
(16,30). 
OSA was significantly associated with hepatocytes’ ballooning, lobular 
inflammation, and fibrosis (32). AHI was a significant positive predictor for fibrosis 
progression independently of obesity and diabetic status (35). Except for AHI, the 
duration of nocturnal hypoxia was also highly associated with NAFLD severity (36). 
Aminoterminal peptide procollagen type 3 as a serum marker of fibrosis was associated 
negatively with oxygen saturation during sleep and positively with AHI and visceral fat, 
indicating realistic risk for steatohepatitis development, especially in those with hepatic 
steatosis (37). According to this, not only the association but NAFLD deterioration from 
simple steatosis to lobular inflammation and fibrosis occurs in OSA patients. The role of 
obesity connecting OSA and NAFLD should not be neglected. Some authors have found 
that only in morbidly obese patients diagnosed with OSA, the progression of steatosis to 
NASH was evident (36). However, when both present, OSA and obesity jointly stimulate 
NAFLD progression (29,35,36).   
Pathophysiologic mechanisms linking OSA and NAFLD are still not 
 completely clarified.  
CIH is an initiator of the vicious circle of oxidative stress, low-grade systemic 
inflammation, and dyslipidemia, processes that are basically present in the progression of 
NAFLD (1,13). On the other hand, insulin resistance as a crucial feature of NAFLD 
stimulates oxidative stress, inflammation, and lipotoxicity (14). Worsening of steatosis in 
OSA happens in conjunction of three processes: increased lipolysis in adipose tissue, 
increased lipid synthesis in the liver, and decreased clearance of lipoproteins from 
circulation (28). Lipolysis of triglycerides into free fatty acids and glycerol in adipose 
tissue stimulated by overactive sympathetic nervous system induces VLDL synthesis in 
the liver. If not incorporated in VLDL, free fatty acids undergo β-oxidation, a metabolic 
process highly activated in insulin resistance state and cause overproduction of reactive 
oxygen species which further exacerbate liver oxidative stress (22). Lipotoxicity drives 
mitochondrial and endoplasmic stress, cellular injury and hepatocellular apoptosis, and 
necrosis. Under these circumstances, hepatic stellate cells actively synthesize collagen 
and other components of the extracellular matrix (elastin, proteoglycans, hyaluronic acid, 
fibronectin, etc) as a healing process (38). In acute hypoxic damage, apoptotic and 




probably occurring in OSA, hepatic stellate cells are being activated and transformed into 
myofibroblasts with proinflammatory and fibrogenic properties. Hepatic stellate cell 
activation happens by inflammatory mediators secreted from Kupffer cells, monocytes, 
platelets, etc., and initiates large amounts of high-density extracellular matrix deposition 
interfering with hepatocytes’ metabolic functions (39).  
CIH induces adipose tissue low-grade inflammation and leads to imbalanced 
production of proinflammatory and anti-inflammatory adipocytokines in favour of the 
former (21). Furthermore, it is assumed that hypoxia in adipose tissue induces inhibition 
of adipogenesis and triglyceride synthesis. In this manner obesity and OSA 
synergistically cause adipocytes death and further deepen insulin resistance, local and 
systemic inflammation (40). Leptin, a hormone secreted by adipocytes, stimulates 
collagen, and tissue inhibitor of metalloproteinase 1 expression in hepatic stellate cells 
(41). It also activates liver macrophages or Kupffer cells to produces profibrogenic 
stimulators, transforming growth factor β (TGF-β) family members which have roles in 
progression from steatosis to steatohepatitis and fibrosis. Although the main effector for 
hepatic stellate cell activation is a platelet-derived growth factor, TGF-β family members 
mediate an epithelial-mesenchymal transition process in hepatocytes that contribute 
directly to hepatic stellate cells to transform into myofibroblasts and produce large 
amounts of extracellular matrix (42). The other adipocytokines also demonstrate a 
disturbed expression profile in the blood due to NAFLD progression. Contrary to leptin, 
levels of adiponectin produced by adipocytes decrease with NAFLD advancement (43). 
As well, its beneficial properties such as anti-inflammatory, anti-steatosis, and insulin-
sensitizing on liver functions and structure weaken. Lower adiponectin levels were related 
to the severe fibrosis stage, lobular or portal inflammation, even HCC. However, due to 
delayed and lower adiponectin clearance by the liver, in the end stage of liver disease 
(cirrhosis), its levels increase. Additionally, CIH initiates multiple cellular signalling 
pathways in the liver and other tissues of which NF-κB is greatly important in NAFLD 
progression (44). Signalling cascade through NF-κB pathway includes activation of 
Kupffer and stellate cells to release inflammatory and fibrogenic mediators (23). This is 
a suitable millie for the fibrosis onset. Predominantly released from adipose tissue and 
smaller extent from the liver, retinol-binding protein (RBP) 4 positively correlates with 
histological liver impairment, hepatic lesions, and fibrosis (43). Visfatin as pro-
inflammatory adipokines produced by various tissues mainly regulates cells’ proliferation 
and glucose homeostasis. It adversely affects glucose metabolism in pancreas β-cells and 
liver, consequently insulin resistance. It stimulates hepatic steatosis and inflammation 
(43). IL-6, pleiotropic proinflammatory cytokine, produced by adipocytes, hepatocytes, 
immune and endothelial cells (45) positively correlates with the degree of inflammation, 
stage of fibrosis, and insulin resistance (25). Also, pro-inflammatory cytokines released 
from activated macrophages (IL-1, IL-6, TNF-α, monocyte chemoattractant protein 1, 




derangements in it (32). All these processes are supported by constant delivery of free 
fatty acids from adipose tissue by portal circulation which stimulate triglyceride synthesis 
and their storage at the beginning and, as insulin resistance persisted, their lipolysis and 
β-oxidation (28,29).   
 
The potential role of gut microbiota linking OSA and NAFLD was assumed as 
detrimental factor for steatosis advancement. Chronic inflammation triggered by 
intestinal endotoxin (bacterial lipopolysaccharide) in conjunction with OSA disrupts 
intestinal mucosa integrity but also stimulates activation of hepatic stellate cells (14). 
However, nocturnal hypoxemia exacerbates chronic inflammation by activating the Toll-
like receptor 4 (TRL 4) signalling pathway. In additive effect with endotoxin, OSA-
stimulated TLR 4 induces cytokines production by Kupffer cells, collagen synthesis by 
activated stellate cells, its deposition, and eventually hepatic fibrosis advancement (46).  
Effects of continuous positive airway pressure (CPAP) on NAFLD status 
Currently, the most effective therapy for OSA is non-invasive ventilation or 
continuous positive airway pressure (CPAP).  CPAP application transfers the air through 
the upper parts of the respiratory tract under a higher pressure than the atmospheric using 
a nasal or oronasal mask during sleeping (47). CPAP increases intraluminal air pressure 
and prevents airway collapse which underlies the OSA development. Also, CPAP 
increases the lung volume at the end of expiration, strengthens the pharyngeal wall, and 
contributes to the improvement of dilator muscle function. All of these improve 
oxyhemoglobin saturation and lowers oxidative stress indicating the basis for the 
favourable environment for better life quality and cardiometabolic state improvement 
(47). Generally observed in so far published papers, data were controversial in obese and 
non-obese individuals as well as in diabetic and non-diabetic ones, respectively using 
CPAP therapy (48). Insulin resistance and metabolic status were improved remarkably in 
OSA non-diabetic and non-obese patients compared to diabetic and obese, indicating 
significant effects not only of OSA but obesity on their development (48). Conflicting 
data were also published about weight loss when CPAP therapy is applied (49,50). Still, 
in mutual effects with different reducing weight protocols, CPAP could ameliorate OSA 
status, its cardiometabolic outcomes, and slow the progression of NAFLD (50). 
CPAP therapy during a couple of months showed beneficial effects on liver 
enzymes status in adults and children (50). The serum ALT levels gradually decreased 
when compared in patients with severe OSA, moderate and mild OSA on adherent CPAP 
therapy (49). The same occurred for AST levels. The opposite was shown after 4 weeks 
of CPAP therapy. No beneficial effects on aminotransferase levels were observed in the 
study by Kohler’s team (51). Besides, the AST-to-platelet ratio, as a determinant of 




partial or poor CPAP adherence (52). Advanced fibrosis bears high mortality risk and 
CPAP could have a pivotal role to reduce overall mortality risk by improving fibrotic 
injuries. However, the other study determined no significant decrease in triglycerides 
content and hepatic steatosis after CPAP (51). Although inconsistent, modest favourable 
effects of CPAP were found on glucose and lipid levels in OSA patients (53). Using 
CPAP, a decrease in inflammation markers (IL-6, CRP TNF-α), oxidative stress                         
(8-isoprostane), and coagulation factors (von Willebrand factor, factors V and VIII) was 
noted (54). It is more likely that liver enzymes status and fibrotic liver damages improve 
with long term adherent CPAP (51). Also, long-term CPAP could ameliorate deleterious 
progression from steatosis to steatohepatitis especially when all cardiometabolic markers 
are improved (50).  
Conclusion 
The pathogenesis of NAFLD is undoubtedly complex and likely involves a complex 
interplay between environmental and genetic factors. It can develop solely as a hepatic 
manifestation of insulin resistance. However, as a comorbid state, NAFLD shares 
metabolic derangements with many other diseases and one of them is OSA. CIH as a 
hallmark of OSA links it to dysregulation of glucose and lipid metabolism, oxidative 
stress, and hepatic inflammation, all of which presents basic features of NAFLD 
development and exacerbation. With the fact that both conditions, OSA and NAFLD are 
highly prevalent in the modern world as global health burden and risk factors for 
cardiovascular disease, it is recommended that all patients with NAFLD should be 
subjected to polysomnographic testing. Still, more well-controlled studies are emerged to 
investigate the relationship and causality between these two conditions, as well as 
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Opstruktivna apneja u snu (OSA) kao oboljenje prevalentno u svetu nosi rizik za nastanak 
kardiovaskularnih i metaboličkih bolesti, povećavajući ukupnu smrtnost. Bolest nealkoholne 
masne jetre (eng. non-alcoholic fatty liver disease - NAFLD) se može smatrati primarnom 
metaboličkom bolešću, ali kao i komorbiditet OSA. Iako prevalenca NAFLD obuhvata četvrtinu 
svetske populacije, ona se povećava sa prisustvom OSA. Pretpostavlja se da su hronična 
intermitentna hipoksija (eng. chronic intermittent hypoxia - CIH) i prekomerna aktivnost 
simpatičkog nervnog sistema uključeni u patogenezu NAFLD i progresiju od steatoze preko 
steatohepatitisa do fibroze. U jetri CIH stvara uslove za oksidativni stres, inflamaciju i povećava 
ekspresiju gena koji učestvuju u sintezi holesterola i masnih kiselina. Kateholamini stimulišu β-
oksidaciju masnih kiselina u jetri i oslobađaju slobodne masne kiseline iz masnog tkiva u plazmu, 
koje inhibiraju dejstva insulina. Gojaznost i insulinska rezistencija kao ključni faktori u razvoju i 
napredovanju NAFLD produbljuju začarani krug oksidativnog stresa, inflamacije i dislipidemije. 
Ako se ne leči, OSA kod pacijenata sa NAFLD je povezana sa inflamacijom, nekrozom hepatocita 
i fibrozom. Kontinuirani pozitivni pritisak vazduha (eng. continuous positive airway pressure - 
CPAP) predstavlja zlatni standard u terapiji OSA, koji omogućava neometani prolaz vazduha kroz 
gornje delove respiratornog sistema. Međutim, CPAP terapija je pokazala da ima povoljne efekte 
na kardiometaboličke ishode i da usporava degeneraciju jetre. 
 
Ključne reči: opstruktivna apneja u snu, hronična intermitentna hipoksija,  
   bolest nealkoholne masne jetre, fibroza 
 
